Recombinant adenoviral-p53 intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma.

Trial Profile

Recombinant adenoviral-p53 intratumoral injection combined with radiotherapy for advanced nasopharyngeal carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2012

At a glance

  • Drugs Contusugene ladenovec (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2012 Planned number of patients changed to 80.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 21 May 2012 Actual end date (31 Oct 2011) added as reported by Chinese Clinical Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top